GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » Institutional Ownership

REGMF (RemeGen Co) Institutional Ownership : 12.97% (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, RemeGen Co's institutional ownership is 12.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, RemeGen Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, RemeGen Co's Float Percentage Of Total Shares Outstanding is 0.00%.


RemeGen Co Institutional Ownership Historical Data

The historical data trend for RemeGen Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Institutional Ownership Chart

RemeGen Co Historical Data

The historical data trend for RemeGen Co can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 12.88 13.05 13.01 13.00 11.06 10.75 10.99 11.10 11.10 11.09

RemeGen Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

From GuruFocus

RemeGen Celebrates World Intellectual Property Day 2023

By PRNewswire PRNewswire 04-26-2023